Loading clinical trials...
Loading clinical trials...
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Conditions
Interventions
Gotistobart
Docetaxel
Locations
152
United States
XCancer/Dothan Hematology & Oncology - 1114
Dothan, Alabama, United States
Genesis Cancer and Blood Institute - 1123
Russellville, Arkansas, United States
The Oncology Institute (TOI) Clinical Research - 1109
Cerritos, California, United States
Emad Ibrahim MD Inc. - 1147
Redlands, California, United States
UC Davis Comprehensive Cancer Center - 1103
Sacramento, California, United States
Bass Medical Group - 1155
Walnut Creek, California, United States
Start Date
June 28, 2023
Primary Completion Date
August 31, 2027
Completion Date
August 31, 2028
Last Updated
April 24, 2026
NCT03340506
NCT06066138
NCT07485114
NCT05098132
NCT06284317
NCT06731413
Lead Sponsor
OncoC4, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions